LUNG
Medical Devices · Healthcare
CFO, COO
2025-11-03–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Pulmonx Corp publishes a filing, an earnings call transcript or a press release.
Get LUNG alertsDerrick Sung is recorded as COO at Pulmonx Corp (LUNG) since November 3, 2025 and CFO at Pulmonx Corp (LUNG). The newest filing on record that lists Derrick Sung as CFO at Pulmonx Corp (LUNG) is dated April 22, 2026. Pulmonx Corp reported in an 8-K filed October 27, 2025 that Derrick Sung was appointed Chief Operating Officer and Chief Financial Officer, effective November 3, 2025. Pulmonx Corp reported in an 8-K filed October 27, 2025 that Derrick Sung was appointed Chief Operating Officer and Chief Financial Officer, effective November 3, 2025. Pulmonx Corp reported in an 8-K filed October 10, 2023 that Derrick Sung resigned as Chief Financial Officer, effective October 10, 2023. The proxy statement of Pulmonx Corp reports total compensation of $2,951,391 for Derrick Sung in fiscal 2025, including a base salary of $83,333. Disclosed compensation is on record for 3 fiscal years. Derrick Sung has spoken on 12 earnings calls and 1 other investor event across 1 company, most recently for Pulmonx Corp on August 11, 2026. Pulmonx Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Pulmonx Corp includes Glendon E. French (CEO and Board Member), Glendon French (CEO and Board Member), Steven S. Williamson (CEO and Board Member) and 4 others.
“the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer, effective November 3, 2025.”
“On October 21, 2025, the Company's Board of Directors appointed Derrick Sung, Ph.D., aged 52, as the Company's Chief Operating Officer and Chief Financial Officer as of November 3, 2025 (the "Sung Effective Date").”
“I'll try and step through each one of those. Let me start by saying that, you know, we're really focused on delivering what we say we're going to deliver and not getting out in front of our skis in terms of the commitments that we make, right?”
“Total worldwide revenue for the 3 months ended June 30, 2023, reached a new quarterly high of $17.2 million, a 23% increase from $14 million in the same period of the prior year.”
“Total worldwide revenue for the three months ended March 31, 2023, was $14.5 million, a 35% increase from $10.8 million in the same period of the prior year and an increase of 37% on a constant currency basis.”
“Total worldwide revenue for the three months ended December 31, 2022, was a record $15.4 million, a 13% increase from $13.7 million in the same period of the prior year, and an increase of 18% on a constant currency basis.”
“Total worldwide revenue for the 3 months ended September 30, 2022, was $13.5 million, a 2% increase from $13.3 million in the same period of the prior year, and an increase of 7% on a constant currency basis.”
2025-11-03–present
Start not stated–present
Last confirmed April 22, 2026
Start not stated–2023-10-10
LUNG
Medical Devices · Healthcare
CFO, COO
2025-11-03–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Pulmonx Corp (LUNG) | Chief Operating Officer and Chief Financial Officer | $83,333 | $2,951,391 |
| 2024 | Pulmonx Corp (LUNG) | Chief Operating Officer and Chief Financial Officer | — | — |
| 2023 | Pulmonx Corp (LUNG) | Former Chief Financial Officer | $357,500 | $2,676,860 |